Opinion|Videos|July 22, 2024
Head-to-head Study of Upadacitnib and Dupilumab in Atopic Dermatitis (Level Up)
Author(s)Christopher G. Bunick, MD, PhD
An atopic dermatitis expert describes the results of the Level Up study, a phase 3b/4 trial comparing upadacitinib and dupilumab, which were recently presented at RAD 2024, focusing on the primary and secondary outcomes of the study.
Advertisement
Episodes in this series
- Head-to-head studies of systemic treatments and studies evaluating sequencing of systemic treatments are rare. Results of one such study, Level Up, were recently presented at RAD 2024. Can you describe the study briefly and discuss primary and secondary outcomes in phase 3b/4 study that compared upadacitnib and dupilumab (
Level Up , RAD 2024)? - What are implications of these results in everyday practice?
Advertisement
Related to this article
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
In this feature, several leaders in the dermatology space were asked how far we have come and where the field is headed in precision medicine.
Iliyan D. Iliev, PhD, discusses how fluconazole targets gut Candida to improve disease activity in IBD.
Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Advertisement
Advertisement
Trending on HCPLive
1
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
2
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
3
Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5